{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:54:50Z","timestamp":1789728890340,"version":"4.0.1"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T00:00:00Z","timestamp":1655164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e0 degli Studi di Bari Aldo Moro"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The \u201cawareness gap\u201d and the under-recognition of chronic kidney disease (CKD) by general practitioners (GPs) is well documented. We set a framework to evaluate the impact in primary care of targeted training and networking with nephrologists with regard to CKD awareness in terms of potential increase of the proportion of patients classified according to KDIGO in the general population and in patients with diabetes, hypertension and heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Data were extracted from the Millewin Digital Platform in use by the GPs (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200917) at baseline (T0,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200917,854) and after 6\u00a0months (T6,\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200918,662) of networking (education, instant messaging and selected joint visits) with nephrologists (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u20092). The following variables were extracted: age, sex, eGFR\u00a0(estimated glomerular filtration rate), ACR\u00a0(urinary albumin-to-creatinine ratio), presence of type 2 diabetes, hypertension and heart failure. The proportion of patients detected having an eGFR below 60\u00a0mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      was also reported as deemed clinically relevant.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We observed an increase in the use of ACR and eGFR tests in the entire cohort (+\u2009121% and\u2009+\u200973%, respectively) and in patients with\u00a0comorbidities. The proportion of patients with eGFR\u2009&lt;\u200960\u00a0mL\/min\/1.73m\n                      <jats:sup>2<\/jats:sup>\n                      significantly increased from 2.2% to 3.8% in the entire cohort, \u00a0from\u00a06.3% to\u00a012.7% in patients with diabetes, and from\u00a05.6% to\u00a09.9% in those with hypertension and finally\u00a0from 10.8% to 23.7% in\u00a0patients with heart failure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Training and network support to GPs by nephrologists can improve CKD awareness and increase its identification in the general population and, even more, in categories at risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01353-6","type":"journal-article","created":{"date-parts":[[2022,6,14]],"date-time":"2022-06-14T12:40:52Z","timestamp":1655210452000},"page":"2057-2065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["\u201cThe Disease Awareness Innovation Network\u201d for chronic kidney disease identification in general practice"],"prefix":"10.1093","volume":"35","author":[{"given":"Francesco","family":"Pesce","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Pasculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Pasculli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"De Nicola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cozzolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Granata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4861-0911","authenticated-orcid":false,"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,6,14]]},"reference":[{"issue":"2","key":"1353_CR1","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrneph.2016.163","volume":"13","author":"RJ Glassock","year":"2017","unstructured":"Glassock RJ, Warnock DG, Delanaye P (2017) The global burden of chronic kidney disease: estimates, variability and pitfalls. Nat Rev Nephrol 13(2):104\u2013114. https:\/\/doi.org\/10.1038\/nrneph.2016.163","journal-title":"Nat Rev Nephrol"},{"issue":"1","key":"1353_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"A Levin","year":"2013","unstructured":"Levin A et al (2013) Kidney Disease improving Global Outcomes (KDIGO) CKD Working Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 3(1):1\u2013150","journal-title":"Kidney Int Suppl"},{"issue":"1","key":"1353_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","volume":"99","author":"MG Shlipak","year":"2021","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, Kengne AP, Madero M, Mihaylova B, Tangri N, Cheung M, Jadoul M, Winkelmayer WC, Zoungas S, Conference Participants (2021) The case for early identification and intervention of chronic kidney disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 99(1):34\u201347. https:\/\/doi.org\/10.1016\/j.kint.2020.10.012","journal-title":"Kidney Int"},{"issue":"1","key":"1353_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1592\/phco.25.1.123.55628","volume":"25","author":"AJ Zillich","year":"2005","unstructured":"Zillich AJ, Saseen JJ, Dehart RM, Dumo P, Grabe DW, Gilmartin C, Hachey DM, Hudson JQ, Pruchnicki MC, Joy MS, Nephrology Practice and research networks of the American college of Clinical Pharmacy (2005) Caring for patients with chronic kidney disease: a joint opinion of the ambulatory care and the nephrology practice and research networks of the American College of Clinical Pharmacy. Pharmacotherapy 25(1):123\u2013143. https:\/\/doi.org\/10.1592\/phco.25.1.123.55628","journal-title":"Pharmacotherapy"},{"issue":"2","key":"1353_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2017-000380","volume":"2","author":"BL Neuen","year":"2017","unstructured":"Neuen BL, Chadban SJ, Demaio AR, Johnson DW, Perkovic V (2017) Chronic kidney disease and the global NCDs agenda. BMJ Glob Health 2(2):e000380. https:\/\/doi.org\/10.1136\/bmjgh-2017-000380","journal-title":"BMJ Glob Health"},{"issue":"4","key":"1353_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.xkme.2021.03.014","volume":"3","author":"CD Chu","year":"2021","unstructured":"Chu CD, Chen MH, McCulloch CE et al (2021) Patient awareness of CKD: a systematic review and meta-analysis of patient-oriented questions and study setting. Kidney Med 3(4):576-585.e1. https:\/\/doi.org\/10.1016\/j.xkme.2021.03.014","journal-title":"Kidney Med"},{"issue":"4","key":"1353_CR7","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/ki.2012.174","volume":"82","author":"L De Nicola","year":"2012","unstructured":"De Nicola L, Minutolo R, Chiodini P, Borrelli S, Zoccali C, Postorino M et al (2012) The effect of increasing age on the prognosis of non-dialysis patients with chronic kidney disease receiving stable nephrology care. Kidney Int 82(4):482\u2013488","journal-title":"Kidney Int"},{"issue":"5","key":"1353_CR8","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/ndt\/gfu383","volume":"30","author":"L De Nicola","year":"2014","unstructured":"De Nicola L, Donfrancesco C, Giampaoli S et al (2014) Prevalence and cardiovascular risk profile of chronic kidney disease in Italy: results of the 2008\u201312 National Health Examination Survey. Nephrol Dial Transpl 30(5):806\u2013814. https:\/\/doi.org\/10.1093\/ndt\/gfu383","journal-title":"Nephrol Dial Transpl"},{"key":"1353_CR9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ije\/dyt025","volume":"43","author":"M Cirillo","year":"2013","unstructured":"Cirillo M et al (2013) Cohort profile: the Gubbio population study. Int J Epidemiol 43:713\u2013720","journal-title":"Int J Epidemiol"},{"issue":"11","key":"1353_CR10","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.2215\/CJN.02400310","volume":"5","author":"G Gambaro","year":"2010","unstructured":"Gambaro G, Yabarek T, Graziani MS, Gemelli A, Abaterusso C, Frigo AC, Marchionna N, Citron L, Bonfante L, Grigoletto F, Tata S, Ferraro PM, Legnaro A, Meneghel G, Conz P, Rizzotti P, D\u2019Angelo A, Lupo A, INCIPE Study Group (2010) Prevalence of CKD in northeastern Italy: results of the INCIPE study and comparison with NHANES. Clin J Am Soc Nephrol 5(11):1946\u20131953. https:\/\/doi.org\/10.2215\/CJN.02400310","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1353_CR11","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/j.ajkd.2008.03.002","volume":"52","author":"R Minutolo","year":"2008","unstructured":"Minutolo R, De Nicola L, Mazzaglia G, Postorino M, Cricelli C, Mantovani LG, Conte G, Cianciaruso B (2008) Detection and awareness of moderate to advanced CKD by primary care practitioners: a cross-sectional study from Italy. Am J Kidney Dis 52(3):444\u2013453. https:\/\/doi.org\/10.1053\/j.ajkd.2008.03.002","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1353_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1053\/j.ajkd.2010.08.022","volume":"57","author":"M Ravera","year":"2011","unstructured":"Ravera M, Noberasco G, Weiss U, Re M, Gallina AM, Filippi A, Cannav\u00f2 R, Ravera G, Cricelli C, Deferrari G (2011) CKD awareness and blood pressure control in the primary care hypertensive population. Am J Kidney Dis 57(1):71\u201377. https:\/\/doi.org\/10.1053\/j.ajkd.2010.08.022","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"1353_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1159\/000490769","volume":"140","author":"M Cozzolino","year":"2018","unstructured":"Cozzolino M, Bolasco P, Ronco C, Conte G, Men\u00e8 P, Mereu MC, Di Luca M, Roccatello D, Rosati A, Jommi C, Costanzo AM, Gualberti G, di Luzio Paparatti U, Remuzzi G (2018) Clinical management of chronic kidney disease patients in Italy: results from the IRIDE Study. Nephron 140(1):39\u201347. https:\/\/doi.org\/10.1159\/000490769","journal-title":"Nephron"},{"issue":"7","key":"1353_CR14","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1681\/ASN.2015050542","volume":"27","author":"K Br\u00fcck","year":"2016","unstructured":"Br\u00fcck K, Stel VS (2016) CKD prevalence varies across the european general population. J Am Soc Nephrol 27(7):2135\u20132147","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1353_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.jrn.2014.05.003","volume":"24","author":"FS Mennini","year":"2014","unstructured":"Mennini FS, Russo S, Marcellusi A, Quintaliani G, Fouque D (2014) Economic effects of treatment of chronic kidney disease with low-protein diet. J Ren Nutr 24(5):313\u2013321","journal-title":"J Ren Nutr"},{"issue":"3","key":"1353_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0230512","volume":"15","author":"S Elshahat","year":"2020","unstructured":"Elshahat S, Cockwell P, Maxwell AP, Griffin M, O\u2019Brien T, O\u2019Neill C (2020) The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. PLoS ONE 15(3):e0230512. https:\/\/doi.org\/10.1371\/journal.pone.0230512","journal-title":"PLoS ONE"},{"issue":"2\u20133","key":"1353_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10754-007-9016-9","volume":"7","author":"G Pontoriero","year":"2007","unstructured":"Pontoriero G, Pozzoni P, Vecchio LD, Locatelli F (2007) International Study of Health Care Organization and Financing for renal replacement therapy in Italy: an evolving reality. Int J Health Care Financ Econ 7(2\u20133):201\u2013215","journal-title":"Int J Health Care Financ Econ"},{"issue":"11","key":"1353_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0110535","volume":"9","author":"LA Szczech","year":"2014","unstructured":"Szczech LA, Stewart RC, Su HL, DeLoskey RJ, Astor BC, Fox CH, McCullough PA, Vassalotti JA (2014) Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease). PLoS ONE 9(11):e110535. https:\/\/doi.org\/10.1371\/journal.pone.0110535","journal-title":"PLoS ONE"},{"issue":"10225","key":"1353_CR19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration (2020) Global, regional, and national burden of chronic kidney disease, 1990\u20132017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395(10225):709\u2013733. https:\/\/doi.org\/10.1016\/S0140-6736(20)30045-3","journal-title":"Lancet"},{"issue":"4","key":"1353_CR20","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1093\/ndt\/gfr765","volume":"27","author":"A Levin","year":"2012","unstructured":"Levin A (2012) Ongoing gaps in CKD and CVD care: re-evaluating strategies for knowledge dissemination. Nephrol Dial Transpl 27(4):1282\u20131284. https:\/\/doi.org\/10.1093\/ndt\/gfr765","journal-title":"Nephrol Dial Transpl"},{"key":"1353_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12875-018-0736-3","volume":"19","author":"C van Dipten","year":"2018","unstructured":"van Dipten C, van Berkel S, de Grauw WJC et al (2018) General practitioners\u2019 perspectives on management of early-stage chronic kidney disease: a focus group study. BMC Fam Pract 19:81. https:\/\/doi.org\/10.1186\/s12875-018-0736-3","journal-title":"BMC Fam Pract"},{"issue":"10","key":"1353_CR22","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s10157-021-02084-x","volume":"25","author":"S Tatematsu","year":"2021","unstructured":"Tatematsu S, Kobayashi K, Utsunomiya Y, Isozaki T, Hatta T, Kusumoto T, Miyazaki M, Hatori N, Otani H (2021) Nationwide questionnaire survey on the management of chronic kidney disease for general practitioners in Japan. Clin Exp Nephrol 25(10):1093\u20131102. https:\/\/doi.org\/10.1007\/s10157-021-02084-x","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"1353_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.2215\/CJN.15031121","volume":"17","author":"AC Reaves","year":"2022","unstructured":"Reaves AC, Weiner DE (2022) Value-based care in chronic kidney disease: missing albuminuria is a missed opportunity. Clin J Am Soc Nephrol 17(1):14\u201316. https:\/\/doi.org\/10.2215\/CJN.15031121","journal-title":"Clin J Am Soc Nephrol"},{"issue":"11","key":"1353_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13012-016-0413-7.PMID:27044401;PMCID:PMC4820872","volume":"4","author":"JY Tsang","year":"2016","unstructured":"Tsang JY, Blakeman T, Hegarty J, Humphreys J, Harvey G (2016) Understanding the implementation of interventions to improve the management of chronic kidney disease in primary care: a rapid realist review. Implement Sci 4(11):47. https:\/\/doi.org\/10.1186\/s13012-016-0413-7.PMID:27044401;PMCID:PMC4820872","journal-title":"Implement Sci"},{"issue":"12","key":"1353_CR25","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.amjmed.2007.04.024","volume":"120","author":"MR Chan","year":"2007","unstructured":"Chan MR, Dall AT, Fletcher KE, Lu N, Trivedi H (2007) Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 120(12):1063\u20131070. https:\/\/doi.org\/10.1016\/j.amjmed.2007.04.024","journal-title":"Am J Med"},{"issue":"1","key":"1353_CR26","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/dom.12583","volume":"18","author":"B Schievink","year":"2016","unstructured":"Schievink B, Kr\u00f6pelin T, Mulder S, Parving HH, Remuzzi G, Dwyer J, Vemer P, de Zeeuw D, Lambers Heerspink HJ (2016) Early renin-angiotensin system intervention is more beneficial than late intervention in delaying end-stage renal disease in patients with type 2 diabetes. Diabetes Obes Metab 18(1):64\u201371. https:\/\/doi.org\/10.1111\/dom.12583","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"1353_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/MNH.0000000000000597","volume":"29","author":"S Curtis","year":"2020","unstructured":"Curtis S, Komenda P (2020) Screening for chronic kidney disease: moving toward more sustainable health care. Curr Opin Nephrol Hypertens 29(3):333\u2013338. https:\/\/doi.org\/10.1097\/MNH.0000000000000597","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"2","key":"1353_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.5414\/CN108831","volume":"86","author":"J Wright Nunes","year":"2016","unstructured":"Wright Nunes J, Roney M, Kerr E, Ojo A, Fagerlin A (2016) A diagnosis of chronic kidney disease: despite fears patients want to know early. Clin Nephrol 86(2):78\u201386. https:\/\/doi.org\/10.5414\/CN108831","journal-title":"Clin Nephrol"},{"issue":"7","key":"1353_CR29","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrneph.2017.63","volume":"13","author":"R Vanholder","year":"2017","unstructured":"Vanholder R, Annemans L, Brown E, Gansevoort R, Gout-Zwart JJ, Lameire N, Morton RL, Oberbauer R, Postma MJ, Tonelli M, Biesen WV, Zoccali C, European Kidney Health Alliance (2017) Reducing the costs of chronic kidney disease while delivering quality health care: a call to action. Nat Rev Nephrol 13(7):393\u2013409. https:\/\/doi.org\/10.1038\/nrneph.2017.63","journal-title":"Nat Rev Nephrol"},{"issue":"7","key":"1353_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10198-016-0830-1","volume":"18","author":"G Turchetti","year":"2017","unstructured":"Turchetti G, Bellelli S, Amato M, Bianchi S, Conti P, Cupisti A, Panichi V, Rosati A, Pizzarelli F, On Behalf of the Tuscany CKD Study Group (2017) The social cost of chronic kidney disease in Italy. Eur J Health Econ 18(7):847\u2013858. https:\/\/doi.org\/10.1007\/s10198-016-0830-1","journal-title":"Eur J Health Econ"},{"issue":"4","key":"1353_CR31","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s41669-017-0062-z","volume":"2","author":"C Jommi","year":"2018","unstructured":"Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, Cozzolino M, Costanzo AM, di Luzio PU, Concas G, Remuzzi G, IRIDE Study Group (2018) The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study. Pharmacoecon Open 2(4):459\u2013467. https:\/\/doi.org\/10.1007\/s41669-017-0062-z","journal-title":"Pharmacoecon Open"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01353-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01353-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:46Z","timestamp":1777564546000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/35\/8\/2057\/8326034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,14]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["1353"],"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01353-6","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,14]]},"assertion":[{"value":"25 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FP received fees from AstraZeneca for lectures. DP, GP have no disclosure. LDN received fees from Astellas, AstraZeneca, Bayer, Novo Nordisk and Vifor for lectures and scientific consultations MC received research funding from Abbvie, Baxter, Keryx, and Shire; reports receiving honoraria from Abbvie, Amgen, Astrazeneca, Baxter, Shire, and Vifor-Pharma; reports serving as a scientific advisor or member of and reports speakers bureau for Abbvie, Amgen, Keryx, Shire, and Vifor Pharma GA received fees from AstraZeneca for lectures LG received research fundings from Abionyx, Sanofi, and received fees from Fresenius, Estor, Werfen, Astellas, AstraZeneca, Travere, Sandoz, Baxter, Mundipharma, Pharmadoc, Retrophin, GSK, Novartis, Chinook.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Patient consent was not required given the non-interventional\/observational nature of the study and the fact that data were provided by the GPs to the investigators as fully anonymised (hence not allowing the study investigators to reconstruct the identity of study participants). Notice was not given to the local Ethics' Committee \/Institutional Review Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}